Improves the chances of reproductive success by selecting chromosomally normal embryos
Selecting normal embryos can increase the pregnancy chances after transfer.
In the general population, 25% of all clinical pregnancies
end in miscarriage.
Some pregnancies with chromosomal anomalies can give rise to the birth of baby with a serious illness.
The time and resources necessary to achieve a pregnancy are reduced.
It helps to avoid repeating cycles of assisted reproduction.
According to internal data and several independent clinical studies, selecting normal embryos might increase the pregnancy possibilities after transfer.
In the general population, 25% of all clinical pregnancies end in miscarriage and almost half are chromosomally abnormal.
Therefore, especially in high-risk groups, the PGS reduces the risk of misscarriage.
The PGS increases the possibility of having a healthy baby, as it allows chromosomally normal embryos to be identified.
The mean theoretical time to achieve a LB (weeks) decreases from 14.9 to 7.7 weeks with PGS (1)
PGS helps to avoid repeating cycles of assisted reproduction and can help to reduce the number of multiple pregnancies performing by supporting single embryo transfer
We use the most advanced technology, NGS (Next-Generation Sequencing) to perform the PGS test:
Our technology and experience allows to analyse 24 chromosomes, in a 12-hour procedure which provides results in more than 99% of cases.
Turn Around Time after receiving the samples in our laboratory: Fresh cases 24-48 hours, as if from Dubai the sample is received on Day-3 then the report is released early morning Day-5
Twin pregnancy is associated with more pregnancy complications and poorer pregnancy outcome than singleton pregnancy.
The development of the IVF techniques and recent studies* demonstrate:
*Selection of single blastocysts for fresh transfer via standard morphology assessment alone and with array CGH for good prognosis IVF patients: results from a randomized pilot study. (Sills ES, Salem RD. 1. Mol Cytogenet. 2012 May 2;5(1):24.)
More infoMultiple pregnancy has increased risks for the mother and the babies:
Scientific publications and documents.
1: Rubio et al: In vitro fertilization with preimplantation genetic diagnosis for aneuploidies in advanced maternal age: a randomized, controlled study.
Fertil Steril. 2017 May;107(5):1122-1129.
2: Rubio et al: Preimplantation genetic screening using fluorescence in situ hybridization inpatients with repetitive implantation failure and advanced maternal age: two randomized trials.
Fertil Steril. 2013 Apr;99(5):1400-7.
3. Yang Z, Liu J, Collins GS, Salem SA, Liu X, Lyle SS, et al. Selection of single blastocysts for fresh transfer via standard morphology assessment alone and with array CGH for good prognosis IVF patients: results from a randomized pilot study.
Mol Cytogenet 2012 May 2; 5(1):24.
4. Coates A, Kung A, Mounts E, Hesla J, Bankowski B, Barbieri E, Ata B, Cohen J, Munné S. Optimal euploid embryo transfer strategy, fresh versus frozen, after preimplantation genetic screening with next generation sequencing: a randomized controlled trial.
Fertil Steril. 2017 Mar;107(3):723-730.e3.
5. Coates A, Bankowski BJ, Kung A, Griffin DK, Munne S. Differences in pregnancy outcomes in donor egg frozen embryo transfer (FET) cycles following preimplantation genetic screening (PGS): a single center retrospective study.
J Assist Reprod Genet. 2017 Jan;34(1):71-78.
Our experts are professional, reliable and approachable and are available to help guide both professionals and patients throughout the entire process. We are proud to deliver high quality results for every test, every day.
embryos analysed/year
IVF cycles/year
years' experience
in genetics
accurate
IGENOMIX is a company that provides
advanced services in reproductive genetics.
In accordance with UK Data Protection Act 1998, we hereby inform the user that his/her personal data will be retained at Igenomix US Ltd only for the purposes of performing the requested genetic services. In addition, the user’s contact details may be subsequently used to send out information about our products and services which could be of a particular interest.
Data holders consent to the treatment of the data provided, guaranteeing and protecting the freedoms and rights marked by current legislation.
The owners of the data consent to the processing of the data provided, thereby guaranteeing and protecting the freedoms and rights defined in the legislation in force.
The owner of the data is entitled to exercise the rights of access, rectification, cancellation and objection by sending a written communication that includes a proof of ID addressed to Igenomix UK, Ltd at the following address: Surrey Technology Centre, 40 Occam Road Guildford, Surrey, GU2 7YG UK or by sending an email to lopd@igenomix.com.
This company guarantees that adequate measures will be adopted to ensure the confidential handling of this data.